Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Fader, AN, Seamon, LG, Escobar, PF, Frasure, HE, Havrilesky, LA, Zanotti, KM, Secord, AA, Boggess, JF, Cohn, DE, Fowler, JM, Skafianos, G, Rossi, E, and Gehrig, PA. "Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers." Gynecol Oncol 126, no. 2 (August 2012): 180-185.

Full Text

Alvarez Secord, A, Berchuck, A, Higgins, RV, Nycum, LR, Kohler, MF, Puls, LE, Holloway, RW, Lewandowski, GS, Valea, FA, and Havrilesky, LJ. "A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer." Cancer 118, no. 13 (July 1, 2012): 3283-3293.

Full Text

Lowery, WJ, Gehrig, PA, Ko, E, Secord, AA, Chino, J, and Havrilesky, LJ. "Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?." Gynecol Oncol 126, no. 1 (July 2012): 12-15.

Full Text

Havrilesky, LJ, Garfield, CF, Barnett, JC, and Cohn, DE. "Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer." Gynecol Oncol 125, no. 3 (June 2012): 631-634.

Full Text

Laskey, RA, Poniewierski, MS, Lopez, MA, Hanna, RK, Secord, AA, Gehrig, PA, Lyman, GH, and Havrilesky, LJ. "Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer." Gynecol Oncol 125, no. 3 (June 2012): 625-630.

Full Text

Chino, JP, Jones, E, Berchuck, A, Secord, AA, and Havrilesky, LJ. "The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer." Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 1872-1879.

Full Text

Berchuck, A, Secord, AA, and Havrilesky, LJ. "Minimally invasive surgery for endometrial cancer: the horse is already out of the barn." J Clin Oncol 30, no. 7 (March 1, 2012): 681-682.

Full Text

Ramirez, PT, Adams, S, Boggess, JF, Burke, WM, Frumovitz, MM, Gardner, GJ, Havrilesky, LJ, Holloway, R, Lowe, MP, Magrina, JF, Moore, DH, Soliman, PT, and Yap, S. "Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force." Gynecol Oncol 124, no. 2 (February 2012): 180-184.

Full Text

Havrilesky, LJ, Pokrzywinski, R, Revicki, D, Higgins, RV, Nycum, LR, Kohler, MF, Berchuck, A, Myers, ER, and Secord, AA. "Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer." Cancer 118, no. 2 (January 15, 2012): 386-391.

Full Text

Behera, MA, Likes, CE, Judd, JP, Barnett, JC, Havrilesky, LJ, and Wu, JM. "Cost analysis of abdominal, laparoscopic, and robotic-assisted myomectomies." J Minim Invasive Gynecol 19, no. 1 (January 2012): 52-57.

Full Text

Pages